Around 50% of adult Mäori in New Zealand are smokers, as compared to around 20% of European New Zealanders. This randomised, placebo-controlled trial assessed the efficacy of bupropion as an intervention for smoking cessation in 134 Mäori smokers (> 10 cigarettes/day) aged 16-70 years. Continued abstinence from smoking at 3 and 12 months were the primary outcome measures. At 3 months, continued abstinence was higher with bupropion (44.3%) than placebo (17.4%), RR 2.54 (95% CI 1.30-5.00). At 12 months abstinence rates were 21.6 and 10.9% for the bupropion and placebo groups respectively, RR 1.99 (95% CI 0.79 to 5.00). In conclusion, the authors suggest that bupropion is an effective treatment for smoking cessation in the indigenous Mäori population in New Zealand.